<DOC>
	<DOCNO>NCT01865747</DOCNO>
	<brief_summary>The purpose study evaluate effect Cabozantinib ( XL184 ) compare Everolimus ( Afinitor ) progression-free survival ( PFS ) overall survival ( OS ) subject advanced renal cell cancer progress prior VEGFR tyrosine kinase inhibitor therapy .</brief_summary>
	<brief_title>A Study Cabozantinib ( XL184 ) v Everolimus Subjects With Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Select 1 . Documented histological cytological diagnosis renal cell cancer clearcell component . 2 . Measurable disease determine investigator . 3 . Must receive least one VEGFRtargeting TKI ( eg , sorafenib , sunitinib , axitinib , pazopanib tivozanib ) . 4 . Recovery toxicity relate prior treatment , unless AE ( ) clinically nonsignificant and/or stable supportive therapy . 5 . Adequate organ marrow function . 6 . Sexually active fertile subject ( male female ) must agree use medically accept method contraception course study 4 month last dose study treatment . 7 . Female subject childbearing potential must pregnant screening . Select 1 . Prior treatment everolimus , specific selective TORC1/PI3K/AKT inhibitor ( eg , temsirolimus ) , cabozantinib . 2 . Receipt type small molecule kinase inhibitor ( include investigational kinase inhibitor ) within 2 week randomization . 3 . Receipt type anticancer antibody ( include investigational antibody ) within 4 week randomization . 4 . Radiation therapy bone metastasis within 2 week , external radiation therapy within 4 week randomization . Systemic treatment radionuclides within 6 week randomization . Subjects clinically relevant ongoing complication prior radiation therapy eligible . 5 . Known brain metastasis cranial epidural disease unless adequately treat radiotherapy and/or surgery stable least 3 month randomization . 6 . Concomitant anticoagulation therapeutic dos oral anticoagulant platelet inhibitor . 7 . Chronic treatment corticosteroid immunosuppressive agent . 8 . Serious illness cancer . 9 . Major surgery within 3 month randomization . Complete wound heal major surgery must occur 1 month randomization minor surgery least 10 day randomization . 10 . Pregnant lactating female . 11 . Diagnosis another malignancy within 2 year randomization , except superficial skin cancer , localize , low grade tumor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>renal cell cancer</keyword>
	<keyword>kidney</keyword>
	<keyword>vascular endothelial growth factor receptor 2 ( VEGFR2 )</keyword>
	<keyword>tyrosine kinase inhibitor</keyword>
	<keyword>hepatocyte growth factor receptor protein ( MET )</keyword>
	<keyword>von Hippel-Lindau gene</keyword>
</DOC>